Study of Oral LOXO-338 in Patients With Advanced Blood Cancers
Conditions: Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-cell Marginal Zone; Lymphoma, Non-Hodgkin; Multiple Myeloma; B-cell Lymphoma; Waldenstrom Macroglobulinemia; Lymphoma, Mantle-Cell Interventions: Drug: LOXO-338; Drug: Pirtobrutinib Sponsors: Eli Lilly and Company; Loxo Oncology, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Chronic Leukemia | Leukemia | Lymphoma | Macroglobulinemia | Myeloma | Oral Cancer | Research | Study | Waldenstrom's Macroglobulinemia